title: Pressure-heart rate responses to alpha-adrenergic stimulation and hormonal regulation in normotensive patients with obstructive sleep apnea.
abstract: Seven normotensive untreated patients with obstructive sleep apnea (OSA) and five control subjects without OSA were compared. Patients with cardiac dilation, chronic airflow limitation, liver and kidney disease, or diabetes mellitus were excluded. Change in pressure-heart rate relation to alpha-adrenergic stimulation (P-HRR), extracellular volume (ECV), and plasma volume (Vp) were measured during daytime. Plasma atrial natriuretic peptide (ANP), plasma renin and aldosterone concentrations were obtained at 1 hour intervals during the night. A mean apnea/hypopnea index (AHI) of 52.2 +/- 23.9/h and a mean lowest arterial oxygen saturation (SaO2) of 61.2 +/- 19.3% (mean +/- SD) were determined from polysomnographic monitoring in the patient group. Release of ANP was significantly higher during sleep in OSA patients than in control subjects (P < .01), with a maximum concentration between 4 and 6 AM in the former. Daytime ECV was significantly higher (P < .05) and Vp significantly lower (P < .05) in OSA patients. Night maximum concentration of ANP (max ANP) was negatively related to AHI (P < .05). P-HRR was negatively related to AHI (P < .05) and positively related to max ANP (P < .05). In conclusion, OSA syndrome alters hormonal system control of body fluid compartment regulation. The decreased response in night max ANP secretion in the most severe OSA patients could be explained by the smaller Vp observed in these patients, decreasing atrial and ventricular pressure loading. Furthermore, alteration of P-HRR, correlated to AHI and max ANP, strengthens the hypothesis that patients who develop hypertension are those in whom the protective mechanism of ANP release failed.
authors.affiliation: Service d'Explorations Fonctionnelles, Hôpital Louis Mourier INSERM U 426, Colombes, France.
authors.forename: D
authors.initials: D
authors.lastname: Maillard
authors.forename: F
authors.initials: F
authors.lastname: Fineyre
authors.forename: D
authors.initials: D
authors.lastname: Dreyfuss
authors.forename: K
authors.initials: K
authors.lastname: Djedaini
authors.forename: F
authors.initials: F
authors.lastname: Blanchet
authors.forename: F
authors.initials: F
authors.lastname: Paycha
authors.forename: J C
authors.initials: JC
authors.lastname: Dussaule
authors.forename: A
authors.initials: A
authors.lastname: Nitenberg
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage*; D000328:Adult; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D012083:Renin / Q000097:blood; D012891:Sleep Apnea Syndromes / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000316:Adrenergic alpha-Agonists; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012083:Renin